Thyroid Cancer Trial Results
Targeted Therapy Shows Benefit in Rare Type of Thyroid Cancer
(Posted: 12/02/2011) - Treatment with the multitargeted agent vandetanib (Caprelsa) improved progression-free survival in patients with medullary thyroid cancer (MTC), according to findings from a randomized clinical trial.
(Posted: 12/02/2011) - Treatment with the multitargeted agent vandetanib (Caprelsa) improved progression-free survival in patients with medullary thyroid cancer (MTC), according to findings from a randomized clinical trial.
Table of Links | |
| 1 | http://www.cancer.gov/clinicaltrials/search |
| 2 | http://www.cancer.gov/cancertopics/types/thyroid |